Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Waters, J. S.
Right arrow Articles by Cotter, F. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Waters, J. S.
Right arrow Articles by Cotter, F. E.
Journal of Clinical Oncology, Vol 18, Issue 9 (May), 2000: 1812-1823
© 2000 American Society for Clinical Oncology

Phase I Clinical and Pharmacokinetic Study of Bcl-2 Antisense Oligonucleotide Therapy in Patients With Non-Hodgkin’s Lymphoma

By Justin S. Waters, Andrew Webb, David Cunningham, Paul A. Clarke, Florence Raynaud, Francesca di Stefano, Finbarr E. Cotter

From the Lymphoma Unit, Royal Marsden Hospital, and Cancer Research Campaign Centre for Cancer Therapeutics, Institute of Cancer Research, Sutton, and Institute of Child Health, London, United Kingdom.

Address reprint requests to David Cunningham, MD, Department of Medicine, Royal Marsden Hospital, Downs Rd, Sutton, Surrey SM2 5PT, United Kingdom; email dcunn{at}icr.ac.uk

PURPOSE: To evaluate the pharmacokinetics and toxicity of an antisense oligonucleotide targeting bcl-2 in patients with non-Hodgkin’s lymphoma (NHL) and to determine efficacy using clinical and biologic end points.

PATIENTS AND METHODS: Twenty-one patients with Bcl-2–positive relapsed NHL received a 14-day subcutaneous infusion of G3139, an 18-mer phosphorothioate oligonucleotide complementary to the first six codons of the bcl-2 open reading frame. Plasma pharmacokinetics were measured by anion exchange high-performance liquid chromatography. Response was assessed by computed tomography. Changes in Bcl-2 expression were measured by fluorescence-activated cell sorting of patients’ tumor samples.

RESULTS: Eight cohorts of patients received doses between 4.6 and 195.8 mg/m2/d. No significant systemic toxicity was seen at doses up to 110.4 mg/m2/d. All patients displayed skin inflammation at the subcutaneous infusion site. Dose-limiting toxicities were thrombocytopenia, hypotension, fever, and asthenia. The maximum-tolerated dose was 147.2 mg/m2/d. Plasma levels of G3139 equivalent to the efficacious plasma concentration in in vivo models were produced with doses above 36.8 mg/m2/d. Plasma levels associated with dose-limiting toxicity were greater than 4 µg/mL. By standard criteria, there was one complete response, 2 minor responses, nine cases of stable disease, and nine cases of progressive disease. Bcl-2 protein was reduced in seven of 16 assessable patients. This reduction occurred in tumor cells derived from lymph nodes in two patients and from peripheral blood or bone marrow mononuclear cell populations in the remaining five patients.

CONCLUSION: Bcl-2 antisense therapy is feasible and shows potential for antitumor activity in NHL. Downregulation of Bcl-2 protein suggests a specific antisense mechanism.




This article has been cited by other articles:


Home page
 Ann OncolHome page
J. Rom, G. von Minckwitz, W. Eiermann, M. Sievert, B. Schlehe, F. Marme, F. Schuetz, A. Scharf, M. Eichbaum, H.-P. Sinn, et al.
Oblimersen combined with docetaxel, adriamycin and cyclophosphamide as neo-adjuvant systemic treatment in primary breast cancer: final results of a multicentric phase I study
Ann. Onc., October 1, 2008; 19(10): 1698 - 1705.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Liu, J. Kolesar, D. G. McNeel, C. Leith, K. Schell, J. Eickhoff, F. Lee, A. Traynor, R. Marnocha, D. Alberti, et al.
A Phase I Pharmacokinetic and Pharmacodynamic Correlative Study of the Antisense Bcl-2 Oligonucleotide G3139, in Combination with Carboplatin and Paclitaxel, in Patients with Advanced Solid Tumors
Clin. Cancer Res., May 1, 2008; 14(9): 2732 - 2739.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
F. Jia, S. D. Figueroa, F. Gallazzi, B. S. Balaji, M. Hannink, S. Z. Lever, T. J. Hoffman, and M. R. Lewis
Molecular Imaging of bcl-2 Expression in Small Lymphocytic Lymphoma Using 111In-Labeled PNA-Peptide Conjugates
J. Nucl. Med., March 1, 2008; 49(3): 430 - 438.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
S. M. Thomas, M. J. Ogagan, M. L. Freilino, S. Strychor, D. R. Walsh, W. E. Gooding, J. R. Grandis, and W. C. Zamboni
Antitumor Mechanisms of Systemically Administered Epidermal Growth Factor Receptor Antisense Oligonucleotides in Combination with Docetaxel in Squamous Cell Carcinoma of the Head and Neck
Mol. Pharmacol., March 1, 2008; 73(3): 627 - 638.
[Abstract] [Full Text] [PDF]

Home page
 Card Surg AdultHome page
J.-C. M. Walkes, W. R. Smythe, and M. J. Reardon
Cardiac Neoplasms
Card. Surg. Adult, January 1, 2008; 3(2008): 1479 - 1510.
[Full Text]

Home page
 J. Immunol.Home page
M. Subramanian and C. Shaha
Up-Regulation of Bcl-2 through ERK Phosphorylation Is Associated with Human Macrophage Survival in an Estrogen Microenvironment
J. Immunol., August 15, 2007; 179(4): 2330 - 2338.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. R. Rheingold, M. D. Hogarty, S. M. Blaney, J. A. Zwiebel, C. Sauk-Schubert, R. Chandula, M. D. Krailo, and P. C. Adamson
Phase I Trial of G3139, a bcl-2 Antisense Oligonucleotide, Combined With Doxorubicin and Cyclophosphamide in Children With Relapsed Solid Tumors: A Children's Oncology Group Study
J. Clin. Oncol., April 20, 2007; 25(12): 1512 - 1518.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
Y. Shao, Y. Wu, C. Y. Chan, K. McDonough, and Y. Ding
Rational design and rapid screening of antisense oligonucleotides for prokaryotic gene modulation
Nucleic Acids Res., November 14, 2006; 34(19): 5660 - 5669.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. M. Mita, L. Ochoa, E. K. Rowinsky, J. Kuhn, G. Schwartz, L. A. Hammond, A. Patnaik, I.-T. Yeh, E. Izbicka, K. Berg, et al.
A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (GenasenseTM, G3139) and irinotecan in patients with metastatic colorectal cancer
Ann. Onc., February 1, 2006; 17(2): 313 - 321.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. W. Yip, J. D. Mocanu, P.Y. B. Au, G. T. Sleep, D. Huang, P. Busson, W.-C. Yeh, R. Gilbert, B. O'Sullivan, P. Gullane, et al.
Combination Bcl-2 Antisense and Radiation Therapy for Nasopharyngeal Cancer
Clin. Cancer Res., November 15, 2005; 11(22): 8131 - 8144.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. M. O'Brien, C. C. Cunningham, A. K. Golenkov, A. G. Turkina, S. C. Novick, and K. R. Rai
Phase I to II Multicenter Study of Oblimersen Sodium, a Bcl-2 Antisense Oligonucleotide, in Patients With Advanced Chronic Lymphocytic Leukemia
J. Clin. Oncol., October 20, 2005; 23(30): 7697 - 7702.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Hachem and R. B. Gartenhaus
Oncogenes as molecular targets in lymphoma
Blood, September 15, 2005; 106(6): 1911 - 1923.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
K. N. Chi, E. Eisenhauer, L. Fazli, E. C. Jones, S. L. Goldenberg, J. Powers, D. Tu, and M. E. Gleave
A Phase I Pharmacokinetic and Pharmacodynamic Study of OGX-011, a 2'-Methoxyethyl Antisense Oligonucleotide to Clusterin, in Patients With Localized Prostate Cancer
J Natl Cancer Inst, September 7, 2005; 97(17): 1287 - 1296.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
M Ocker, D Neureiter, M Lueders, S Zopf, M Ganslmayer, E G Hahn, C Herold, and D Schuppan
Variants of bcl-2 specific siRNA for silencing antiapoptotic bcl-2 in pancreatic cancer
Gut, September 1, 2005; 54(9): 1298 - 1308.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Z. Badros, O. Goloubeva, A. P. Rapoport, B. Ratterree, N. Gahres, B. Meisenberg, N. Takebe, M. Heyman, J. Zwiebel, H. Streicher, et al.
Phase II Study of G3139, a Bcl-2 Antisense Oligonucleotide, in Combination With Dexamethasone and Thalidomide in Relapsed Multiple Myeloma Patients
J. Clin. Oncol., June 20, 2005; 23(18): 4089 - 4099.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. A. Desai, R. L. Schilsky, A. Young, L. Janisch, W. M. Stadler, N. J. Vogelzang, S. Cadden, J. A. Wright, and M. J. Ratain
A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors
Ann. Onc., June 1, 2005; 16(6): 958 - 965.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Marcucci, W. Stock, G. Dai, R. B. Klisovic, S. Liu, M. I. Klisovic, W. Blum, C. Kefauver, D. A. Sher, M. Green, et al.
Phase I Study of Oblimersen Sodium, an Antisense to Bcl-2, in Untreated Older Patients With Acute Myeloid Leukemia: Pharmacokinetics, Pharmacodynamics, and Clinical Activity
J. Clin. Oncol., May 20, 2005; 23(15): 3404 - 3411.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. W. Tolcher, K. Chi, J. Kuhn, M. Gleave, A. Patnaik, C. Takimoto, G. Schwartz, I. Thompson, K. Berg, S. D'Aloisio, et al.
A Phase II, Pharmacokinetic, and Biological Correlative Study of Oblimersen Sodium and Docetaxel in Patients with Hormone-Refractory Prostate Cancer
Clin. Cancer Res., May 15, 2005; 11(10): 3854 - 3861.
[Abstract] [Full Text] [PDF]

Home page
 CA Cancer J ClinHome page
I. M. Ghobrial, T. E. Witzig, and A. A. Adjei
Targeting Apoptosis Pathways in Cancer Therapy
CA Cancer J Clin, May 1, 2005; 55(3): 178 - 194.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Dai, K. K. Chan, S. Liu, D. Hoyt, S. Whitman, M. Klisovic, T. Shen, M. A. Caligiuri, J. Byrd, M. Grever, et al.
Cellular Uptake and Intracellular Levels of the Bcl-2 Antisense G3139 in Cultured Cells and Treated Patients with Acute Myeloid Leukemia
Clin. Cancer Res., April 15, 2005; 11(8): 2998 - 3008.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. W. Friedberg, H. Kim, M. McCauley, E. M. Hessel, P. Sims, D. C. Fisher, L. M. Nadler, R. L. Coffman, and A. S. Freedman
Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-{alpha}/{beta}-inducible gene expression, without significant toxicity
Blood, January 15, 2005; 105(2): 489 - 495.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. A. DiVito, A. J. Berger, R. L. Camp, M. Dolled-Filhart, D. L. Rimm, and H. M. Kluger
Automated Quantitative Analysis of Tissue Microarrays Reveals an Association between High Bcl-2 Expression and Improved Outcome in Melanoma
Cancer Res., December 1, 2004; 64(23): 8773 - 8777.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. R. Smith, F. Jin, and I. Joshi
Enhanced efficacy of therapy with antisense BCL-2 oligonucleotides plus anti-CD20 monoclonal antibody in scid mouse/human lymphoma xenografts
Mol. Cancer Ther., December 1, 2004; 3(12): 1693 - 1699.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S. Rao, D. Watkins, D. Cunningham, D. Dunlop, P. Johnson, P. Selby, B. W. Hancock, C. Fegan, D. Culligan, S. Schey, et al.
Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphoma
Ann. Onc., September 1, 2004; 15(9): 1413 - 1418.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. Marshall, H. Chen, D. Yang, M. Figueira, K. B. Bouker, Y. Ling, M. Lippman, S. R. Frankel, and D. F. Hayes
A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors
Ann. Onc., August 1, 2004; 15(8): 1274 - 1283.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. W. Tolcher, J. Kuhn, G. Schwartz, A. Patnaik, L. A. Hammond, I. Thompson, H. Fingert, D. Bushnell, S. Malik, J. Kreisberg, et al.
A Phase I Pharmacokinetic and Biological Correlative Study of Oblimersen Sodium (Genasense, G3139), an Antisense Oligonucleotide to the Bcl-2 mRNA, and of Docetaxel in Patients with Hormone-Refractory Prostate Cancer
Clin. Cancer Res., August 1, 2004; 10(15): 5048 - 5057.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
W. R. Parulekar and E. A. Eisenhauer
Phase I Trial Design for Solid Tumor Studies of Targeted, Non-Cytotoxic Agents: Theory and Practice
J Natl Cancer Inst, July 7, 2004; 96(13): 990 - 997.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Thallinger, M. F. Wolschek, H. Maierhofer, H. Skvara, H. Pehamberger, B. P. Monia, B. Jansen, V. Wacheck, and E. Selzer
Mcl-1 Is a Novel Therapeutic Target for Human Sarcoma: Synergistic Inhibition of Human Sarcoma Xenotransplants by a Combination of Mcl-1 Antisense Oligonucleotides with Low-Dose Cyclophosphamide
Clin. Cancer Res., June 15, 2004; 10(12): 4185 - 4191.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. M. Rudin, M. Kozloff, P. C. Hoffman, M. J. Edelman, R. Karnauskas, R. Tomek, L. Szeto, and E. E. Vokes
Phase I Study of G3139, a bcl-2 Antisense Oligonucleotide, Combined With Carboplatin and Etoposide in Patients With Small-Cell Lung Cancer
J. Clin. Oncol., March 15, 2004; 22(6): 1110 - 1117.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
R. L. Hayward, J. S. Macpherson, J. Cummings, B. P. Monia, J. F. Smyth, and D. I. Jodrell
Enhanced oxaliplatin-induced apoptosis following antisense Bcl-xl down-regulation is p53 and Bax dependent: Genetic evidence for specificity of the antisense effect
Mol. Cancer Ther., February 1, 2004; 3(2): 169 - 178.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. J. Waxman and P. S. Schwartz
Harnessing Apoptosis for Improved Anticancer Gene Therapy
Cancer Res., December 15, 2003; 63(24): 8563 - 8572.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Niwa, A. L. Wentzel, M. Li, W. E. Gooding, V. W. Y. Lui, and J. R. Grandis
Antitumor Effects of Epidermal Growth Factor Receptor Antisense Oligonucleotides in Combination with Docetaxel in Squamous Cell Carcinoma of the Head and Neck
Clin. Cancer Res., October 15, 2003; 9(13): 5028 - 5035.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
C. A. Burkhart, A. J. Cheng, J. Madafiglio, M. Kavallaris, M. Mili, G. M. Marshall, W. A. Weiss, L. M. Khachigian, M. D. Norris, and M. Haber
Effects of MYCN Antisense Oligonucleotide Administration on Tumorigenesis in a Murine Model of Neuroblastoma
J Natl Cancer Inst, September 17, 2003; 95(18): 1394 - 1403.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Goel, K. Desai, A. Bulgaru, A. Fields, G. Goldberg, S. Agrawal, R. Martin, M. Grindel, and S. Mani
A Safety Study of a Mixed-backbone Oligonucleotide (GEM231) Targeting the Type I Regulatory Subunit {alpha} of Protein Kinase A Using a Continuous Infusion Schedule in Patients with Refractory Solid Tumors
Clin. Cancer Res., September 15, 2003; 9(11): 4069 - 4076.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. A. Shabbits, Y. Hu, and L. D. Mayer
Tumor Chemosensitization Strategies Based on Apoptosis Manipulations
Mol. Cancer Ther., August 1, 2003; 2(8): 805 - 813.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. L. Hayward, J. S. Macpherson, J. Cummings, B. P. Monia, J. F. Smyth, and D. I. Jodrell
Antisense Bcl-xl Down-Regulation Switches the Response to Topoisomerase I Inhibition from Senescence to Apoptosis in Colorectal Cancer Cells, Enhancing Global Cytotoxicity
Clin. Cancer Res., July 1, 2003; 9(7): 2856 - 2865.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Q. Liu and Y. Gazitt
Potentiation of dexamethasone-, paclitaxel-, and Ad-p53-induced apoptosis by Bcl-2 antisense oligodeoxynucleotides in drug-resistant multiple myeloma cells
Blood, May 15, 2003; 101(10): 4105 - 4114.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Loomis, R. Carbone, M. Reiss, and J. Lacy
Bcl-2 Antisense (G3139, Genasense) Enhances the in Vitro and in Vivo Response of Epstein-Barr Virus-associated Lymphoproliferative Disease to Rituximab
Clin. Cancer Res., May 1, 2003; 9(5): 1931 - 1939.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Tortora, R. Caputo, V. Damiano, R. Caputo, T. Troiani, B. M. Veneziani, S. De Placido, A. R. Bianco, U. Zangemeister-Wittke, and F. Ciardiello
Combined Targeted Inhibition of bcl-2, bcl-XL, Epidermal Growth Factor Receptor, and Protein Kinase A Type I Causes Potent Antitumor, Apoptotic, and Antiangiogenic Activity
Clin. Cancer Res., February 1, 2003; 9(2): 866 - 871.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
G. Marcucci, J. C. Byrd, G. Dai, M. I. Klisovic, P. J. Kourlas, D. C. Young, S. R. Cataland, D. B. Fisher, D. Lucas, K. K. Chan, et al.
Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia
Blood, January 15, 2003; 101(2): 425 - 432.
[Abstract] [Full Text] [PDF]

Home page
 J. Dent. Res.Home page
S. Xi and J.R. Grandis
Gene Therapy for the Treatment of Oral Squamous Cell Carcinoma
J. Dent. Res., January 1, 2003; 82(1): 11 - 16.
[Abstract] [Full Text] [PDF]

Home page
 Card Surg AdultHome page
M. J. Reardon and W. R. Smythe
Cardiac Neoplasms
Card. Surg. Adult, January 1, 2003; 2(2003): 1373 - 1400.
[Full Text]

Home page
 BloodHome page
M. Ladetto, P. Corradini, S. Vallet, F. Benedetti, U. Vitolo, M. Martelli, M. Brugiatelli, P. Coser, A. Perrotti, I. Majolino, et al.
High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO)
Blood, August 13, 2002; 100(5): 1559 - 1565.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
Q. Hu, M. B. Bally, and T. D. Madden
Subcellular trafficking of antisense oligonucleotides and down-regulation of bcl-2 gene expression in human melanoma cells using a fusogenic liposome delivery system
Nucleic Acids Res., August 1, 2002; 30(16): 3632 - 3641.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
J. M. KAMINSKI, M. R. HUBER, J. B. SUMMERS, and M. B. WARD
Design of a nonviral vector for site-selective, efficient integration into the human genome
FASEB J, August 1, 2002; 16(10): 1242 - 1247.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
B. Jahrsdorfer, R. Jox, L. Muhlenhoff, K. Tschoep, A. Krug, S. Rothenfusser, G. Meinhardt, B. Emmerich, S. Endres, and G. Hartmann
Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN
J. Leukoc. Biol., July 1, 2002; 72(1): 83 - 92.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. K. Dy and A. A. Adjei
Novel Targets for Lung Cancer Therapy: Part II
J. Clin. Oncol., July 1, 2002; 20(13): 3016 - 3028.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. G. Ferreira, M. Epping, F. A. E. Kruyt, and G. Giaccone
Apoptosis: Target of Cancer Therapy
Clin. Cancer Res., July 1, 2002; 8(7): 2024 - 2034.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Derenne, B. Monia, N. M. Dean, J. K. Taylor, M.-J. Rapp, J.-L. Harousseau, R. Bataille, and M. Amiot
Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-xL is an essential survival protein of human myeloma cells
Blood, June 17, 2002; 100(1): 194 - 199.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
W. R. Smythe, I. Mohuiddin, M. Ozveran, and X. X. Cao
Antisense therapy for malignant mesothelioma with oligonucleotides targeting the bcl-xl gene product
J. Thorac. Cardiovasc. Surg., June 1, 2002; 123(6): 1191 - 1198.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
F. Ciardiello and G. Tortora
Inhibition of bcl-2 as cancer therapy
Ann. Onc., April 1, 2002; 13(4): 501 - 502.
[Full Text] [PDF]

Home page
 Ann OncolHome page
C. M. Rudin, G. A. Otterson, A. M. Mauer, M. A. Villalona-Calero, R. Tomek, B. Prange, C. M. George, L. Szeto, and E. E. Vokes
A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer
Ann. Onc., April 1, 2002; 13(4): 539 - 545.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Mohammad, Y. Abubakr, M. Dan, A. Aboukameel, C. Chow, A. Mohamed, N. Hamdy, and A. Al-Katib
Bcl-2 Antisense Oligonucleotides Are Effective against Systemic but not Central Nervous System Disease in Severe Combined Immunodeficient Mice Bearing Human t(14;18) Follicular Lymphoma
Clin. Cancer Res., April 1, 2002; 8(4): 1277 - 1283.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. J. Morris, W. P. Tong, C. Cordon-Cardo, M. Drobnjak, W. K. Kelly, S. F. Slovin, K. L. Terry, K. Siedlecki, P. Swanson, M. Rafi, et al.
Phase I Trial of BCL-2 Antisense Oligonucleotide (G3139) Administered by Continuous Intravenous Infusion in Patients with Advanced Cancer
Clin. Cancer Res., March 1, 2002; 8(3): 679 - 683.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. M. Luger, S. G. O'Brien, J. Ratajczak, M. Z. Ratajczak, R. Mick, E. A. Stadtmauer, P. C. Nowell, J. M. Goldman, and A. M. Gewirtz
Oligodeoxynucleotide-mediated inhibition of c-